WO2006005621A3 - Verfahren zur herstellung von albumin-corticoid-konjugaten - Google Patents

Verfahren zur herstellung von albumin-corticoid-konjugaten Download PDF

Info

Publication number
WO2006005621A3
WO2006005621A3 PCT/EP2005/007679 EP2005007679W WO2006005621A3 WO 2006005621 A3 WO2006005621 A3 WO 2006005621A3 EP 2005007679 W EP2005007679 W EP 2005007679W WO 2006005621 A3 WO2006005621 A3 WO 2006005621A3
Authority
WO
WIPO (PCT)
Prior art keywords
corticoid
conjugates
producing albumen
albumen
producing
Prior art date
Application number
PCT/EP2005/007679
Other languages
English (en)
French (fr)
Other versions
WO2006005621A2 (de
Inventor
Hannsjoerg Sinn
Original Assignee
Hannsjoerg Sinn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hannsjoerg Sinn filed Critical Hannsjoerg Sinn
Priority to US11/632,443 priority Critical patent/US20080051376A1/en
Priority to CA002573605A priority patent/CA2573605A1/en
Priority to EP05763576A priority patent/EP1765410A2/de
Publication of WO2006005621A2 publication Critical patent/WO2006005621A2/de
Publication of WO2006005621A3 publication Critical patent/WO2006005621A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft Corticoid-Transportprotein-Konjugate, Verfahren zur ihrer Herstellung sowie ihrer Verwendung in der Medizin, insbesondere zur Therapie von Tumoren von entzündlichen Prozessen und zur Immunsuppression.
PCT/EP2005/007679 2004-07-14 2005-07-14 Verfahren zur herstellung von albumin-corticoid-konjugaten WO2006005621A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/632,443 US20080051376A1 (en) 2004-07-14 2005-07-14 Method for Producing Albumin-Corticoid Conjugates
CA002573605A CA2573605A1 (en) 2004-07-14 2005-07-14 Method for producing albumen/corticoid conjugates
EP05763576A EP1765410A2 (de) 2004-07-14 2005-07-14 Verfahren zur herstellung von albumin-corticoid-konjugaten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004034008.0 2004-07-14
DE102004034008A DE102004034008A1 (de) 2004-07-14 2004-07-14 Verfahren zur Herstellung von Albumin-Corticoid-Konjugaten

Publications (2)

Publication Number Publication Date
WO2006005621A2 WO2006005621A2 (de) 2006-01-19
WO2006005621A3 true WO2006005621A3 (de) 2007-03-15

Family

ID=35466082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007679 WO2006005621A2 (de) 2004-07-14 2005-07-14 Verfahren zur herstellung von albumin-corticoid-konjugaten

Country Status (5)

Country Link
US (1) US20080051376A1 (de)
EP (1) EP1765410A2 (de)
CA (1) CA2573605A1 (de)
DE (1) DE102004034008A1 (de)
WO (1) WO2006005621A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
US11986536B2 (en) * 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (de) * 2019-03-23 2020-09-30 Ablevia biotech GmbH Verbindung zur sequestrierung von unerwünschten antikörpern in einem patienten

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326618A1 (de) * 1987-03-04 1989-08-09 Nippon Hypox Laboratories Incorporated Medizinische zusammensetzung, welche albumin als träger enthält, und verfahren zu deren herstellung
EP0482540A1 (de) * 1990-10-25 1992-04-29 LABORATORI BALDACCI Spa Neue Derivative von Corticosteroiden, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzung
WO2004006966A1 (en) * 2002-07-16 2004-01-22 Medexis S.A. Steroid conjugates, preparation thereof and the use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
CA2283597C (en) * 1998-10-02 2008-02-05 Ortho-Clinical Diagnostics, Inc. Reduced cortisol conjugates
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326618A1 (de) * 1987-03-04 1989-08-09 Nippon Hypox Laboratories Incorporated Medizinische zusammensetzung, welche albumin als träger enthält, und verfahren zu deren herstellung
EP0482540A1 (de) * 1990-10-25 1992-04-29 LABORATORI BALDACCI Spa Neue Derivative von Corticosteroiden, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzung
WO2004006966A1 (en) * 2002-07-16 2004-01-22 Medexis S.A. Steroid conjugates, preparation thereof and the use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MELGERT B N ET AL: "Cellular distribution and handling of liver-targeting preparations in human livers studied by a liver lobe perfusion", DRUG METABOLISM AND DISPOSITION, vol. 29, no. 4 I, 2001, pages 361 - 367, XP008072282, ISSN: 0090-9556 *
MELGERT BARBRO N ET AL: "Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cells", JOURNAL OF HEPATOLOGY, vol. 32, no. 4, April 2000 (2000-04-01), pages 603 - 611, XP002410082, ISSN: 0168-8278 *
MELGERT ET AL: "Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats", HEPATOLOGY, vol. 34, no. 4, October 2001 (2001-10-01), pages 719 - 728, XP005199422, ISSN: 0270-9139 *
RODRIGUEZ M L ET AL: "Generic immunoassay of corticosteroids with minimum pre-treatment of urine samples", ANALYST, vol. 119, no. 12, 1994, pages 2631 - 2634, XP008070792, ISSN: 0003-2654 *

Also Published As

Publication number Publication date
DE102004034008A1 (de) 2006-02-09
EP1765410A2 (de) 2007-03-28
US20080051376A1 (en) 2008-02-28
CA2573605A1 (en) 2006-01-19
WO2006005621A2 (de) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2007025977A8 (en) Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2005027966A3 (en) Antibodies with altered effector functions
WO2005097832A3 (en) Humanized anti-tgf-beta antibodies
WO2007007173A3 (en) Human anti-madcam antibodies
WO2006083971A3 (en) Dr5 antibodies and uses thereof
WO2007112757A3 (en) A process for concentration of a polypeptide
WO2008070042A3 (en) High potency recombinant antibodies, methods for producing them and use in cancer therapy
WO2007022529A3 (en) Method of treating inflammatory diseases
WO2005111083A3 (en) Antibodies specific for glycoprotein vi and methods of producing these antibodies
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2005003298A3 (en) Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease
NZ599875A (en) Human il-23 antigen binding proteins
WO2004071382A3 (en) Substituted heterocycles
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
HK1106253A1 (en) Desoxo-nonadepsipeptides
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
ATE468398T1 (de) Herstellungsverfahren zur produktion aktiver und löslicher proteine in prokaryonten und polycistronische vektoren dafür
TW200621799A (en) Acylated nonadepsipeptides II
WO2006050826A3 (de) Behandlung von mastitis mit enrofloxacin
WO2008028934A8 (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
WO2005118613A3 (de) Antibakterielle amid-makrozyklen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2573605

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11632443

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005763576

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005763576

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11632443

Country of ref document: US